4-Aryl-4H-naphthopyrans derivatives: One-pot synthesis, evaluation of Src kinase inhibitory and anti-proliferative activities

DARU, Journal of Pharmaceutical Sciences

Volumn 20, Issue 1, 2012, Pages

  Rafinejad, Ali ^a   Fallah Tafti, Asal ^a   Tiwari, Rakesh ^b   Shirazi, Amir Nasrolahi ^b   Mandal, Deendayal ^b   Shafiee, Abbas ^a   Parang, Keykavous ^b   Foroumadi, Alireza ^a   Akbarzadeh, Tahmineh ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

Anticancer activity; Carbonitrile; Naphthopyrans; Protein kinase; Src kinase

Indexed keywords

2 AMINO 4 ARYL 4H NAPHTOPYRAN 3 CARBONITRILE DERIVATIVE; ALDEHYDE; ANTINEOPLASTIC AGENT; DOXORUBICIN; NAPHTHALENE DERIVATIVE; PHOSPHATE; PHOSPHOTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER CELL LINE; BREAST CARCINOMA; CELL PROLIFERATION ASSAY; CHEMICAL STRUCTURE; DRUG SCREENING; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IC 50; MASS SPECTROMETRY; ONCOGENE SRC; ONE POT SYNTHESIS; PROTON NUCLEAR MAGNETIC RESONANCE; STRUCTURE ACTIVITY RELATION;

EID: 84878544941     PISSN: 15608115     EISSN: 20082231     Source Type: Journal    
DOI: 10.1186/2008-2231-20-100     Document Type: Article

References (38)

1. Yeatman TJ: A renaissance for SRC. Nat Rev Cancer 2004, 4:470-480. (Pubitemid 38745532)
2. Yu CL, Meyer DJ, Campbell GS, Larner AC, Carter-Su C, Schwartz J, Jove R: Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science 1995, 269:81-83.
3. Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, Zhang S, Wang T, Sinibaldi D, Coppola D, Heller R, Ellis LM, Karras J, Bromberg J, Pardoll D, Jove R, Yu H: Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 2002, 21:2000-2008. (Pubitemid 34270888)
4. Russello SV, Shore SK: SRC in human carcinogenesis. Front Biosci 2004, 9:139-144. (Pubitemid 38925447)
5. Tsygankov AY, Shore SK: Src: regulation, role in human carcinogenesis and pharmacological inhibitors. Curr Pharm Des 2004, 10:1745-1756. (Pubitemid 38647457)
6. Boyer B, Valles AM, Edme N: Induction and regulation of epithelialmesenchymal transitions. Biochem Pharmacol 2000, 60:1091-1099.
7. Johnson FM, Gallick GE: SRC family nonreceptor tyrosine kinases as molecular targets for cancer therapy. Anticancer Agents Med Chem 2007, 7:651-659. (Pubitemid 350237770)
8. Nam JS, Ino Y, Sakamoto M, Hirohashi S: Src family kinase inhibitor PP2 restores the E-cadherin/catenin cell adhesion system in human cancer cells and reduces cancer metastasis. Clin Cancer Res 2002, 8:2430-2436. (Pubitemid 34753619)
9. Coluccia AM, Benati D, Dekhil H, De Filippo A, Lan C, Gambacorti-Passerini C: SKI-606 decreases growth and motility of colorectal cancer cells by preventing pp 60(c-Src)-dependent tyrosine phosphorylation of betacatenin and its nuclear signaling. Cancer Res 2006, 66:2279-2286.
10. Gonzalez L, Agullo-Ortuno MT, Garcia-Martinez JM, Calcabrini A, Gamallo C, Palacios J, Aranda A, Martin-Perez J: Role of c-Src in human MCF7 breast cancer cell tumorigenesis. J Biol Chem 2006, 281:20851-20864. (Pubitemid 44115426)
11. Benati D, Baldari CT: SRC family kinases as potential therapeutic targets for malignancies and immunological disorders. Curr Med Chem 2008, 15:1154-1165. (Pubitemid 351997805)
12. Sundaramoorthi R, Shakespeare WC, Keenan TP, Metcalf CA III, Wang Y, Mani U, Taylor M, Liu S, Bohacek RS, Narula SS, Dalgarno DC, van Schravandijk MR, Violette SM, Liou S, Adams S, Ram MK, Keats JA, Weigle M, Sawyer TK, Weigele M: Bone-Targeted Src kinase inhibitors: novel pyrroloand pyrazolopyrimidine analogues. Bioorg Med Chem Lett 2003, 13:3063-3066. (Pubitemid 36993637)
13. Schenone S, Bruno O, Ranise A, Bondavalli F, Brullo C, Fossa P, Mosti L, Menozzi G, Carraro F, Naldini A, Bernini C, Manetti F, Botta M: New pyrazolo [3, 4-d]pyrimidines endowed with A431 antiproliferative activity and inhibitory properties of Src phosphorylation. Bioorg Med Chem Lett 2004, 14:2511-2517. (Pubitemid 38515694)
14. Ple PA, Green TP, Hennequin LF, Curwen J, Fennell M, Allen J, Lambert-Van Der Brempt C, Costello G: Discovery of a new class of anilinoquinazoline inhibitors with high affinity and specificity for the tyrosine kinase domain of c-Src. J Med Chem 2004, 47:871-887. (Pubitemid 38176790)
15. Hennequin LF, Allen J, Breed J, Curwen J, Fennell M, Green TP, Lambert-van Der Brempt C, Morgentin R, Norman RA, Olivier A, Otterbein L, Ple PA, Warin N, Costello G: N-(5-chloro-1, 3-benzodioxol-4-yl)-7-[2-(4- methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin- 4-Amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor. J Med Chem 2006, 49:6465-6488.
16. Barrios Sosa AC, Boschelli DH, Wu B, Wang Y, Golas JM: Further studies on ethenyl and ethynyl-4-phenylamino-3-quinolinecarbonitriles: identification of a subnanomolar Src kinase inhibitor. Bioorg Med Chem Lett 2005, 15:1743-1747. (Pubitemid 40312563)
17. Boschelli DH, Wu B, Ye F, Durutlic H, Golas JM, Lucas J, Boschelli F: Facile preparation of new 4-phenylamino-3-quinolinecarbonitrile Src kinase inhibitors via 7-fluoro intermediates: identification of potent 7-Amino analogs. Bioorg Med Chem 2008, 16:405-412.
18. Boschelli DH, Wang D, Wang Y, Wu B, Honores EE, Barrios Sosa AC, Chaudhary I, Golas J, Lucas J, Boschelli F: Optimization of 7-Alkene-3- quinolinecarbonitriles as Src kinase inhibitors. Bioorg Med Chem Lett 2010, 20:2924-2927.
19. Dulsat C, Mealy N, Castaner R: Saracatinib. Dual Src/ABL kinase inhibitor, Oncolytic. Drugs Fut 2009, 34:106-114.
20. Boschelli DH, Ye F, Wang YD, Dutia M, Johnson SL, Wu B, Miller K, Powell DW, Yaczko D, Young M, Tischler M, Arndt K, Discafani C, Etienne C, Gibbons J, Grod J, Lucas J, Weber JM, Boschelli F: Optimization of 4- phenylamino-3- quinolinecarbonitriles as potent inhibitors of Src kinase activity. J Med Chem 2001, 44:3965-3977. (Pubitemid 33051486)
21. Boschelli DH, Boschelli F: Bosutinib. Dual Src and Abl kinase inhibitor, treatment of solid tumors, treatment of CML and Ph+ ALL. Drugs Fut 2007, 32:481-490. (Pubitemid 47234738)
22. Lawrence DS, Niu J: Protein kinase inhibitors: The tyrosine-specific protein kinases. Pharmacol Ther 1998, 77:81-114. (Pubitemid 28077909)
23. Brunton VG, Lear MJ, McKeown P, Robins DJ, Workman P: Synthesis and antiproliferative activity of tyrphostins containing quinoline moieties. Anticancer Drug Des 1996, 11:463-483. (Pubitemid 26320793)
24. Morin MJ: From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-Tumor and anti-Angiogenic agents. Oncogene 2000, 19:6574-6583. (Pubitemid 32197695)
25. Dell CP: Antiproliferative naphthopyrans: biological activity, mechanistic studies and therapeutic potential. Current Med Chem 1998, 5:179-194. (Pubitemid 28238488)
26. Wiernicki TR, Bean JS, Dell C, Williams A, Wood D, Kauffman RF, Singh JP: Inhibition of vascular smooth muscle cell proliferation and arterial intimal thickening by a novel antiproliferative naphthopyran. J Pharmacol Exp Ther 1996, 278:1452-1459. (Pubitemid 27167000)
27. Fallah-Tafti A, Tiwari R, Shirazi AN, Akbarzadeh T, Mandal D, Shafiee A, Parang K, Foroumadi A: 4-Aryl-4H-chromene-3-carbonitrile derivatives: evaluation of Src kinase inhibitory and anticancer activities. Med Chem 2011, 7:466-472.
28. Fallah-Tafti A, Foroumadi A, Tiwari R, Shirazi AN, Hangauer DG, Bu Y, Akbarzadeh T, Parang K, Shafiee A: Thiazolyl N-benzyl-substituted acetamide derivatives: synthesis, Src kinase inhibitory and anticancer activities. Eur J Med Chem 2011, 46:4853-4858.
29. Kumar D, Reddy VB, Kumar A, Mandal D, Tiwari R, Parang K: Click chemistry inspired one-pot synthesis of 1, 4-disubstituted 1, 2, 3-Triazoles and their Src kinase inhibitory activity. Bioorg Med Chem Lett 2011, 21:449-452.
30. Sharma D, Sharma RK, Bhatia S, Tiwari R, Mandal D, Lehmann J, Parang K, Olsen CE, Parmar VS, Prasad AK: Synthesis, Src kinase inhibitory and anticancer activities of 1-substituted 3-(N-Alkyl-N-phenylamino)propane- 2-ols. Biochimie 2010, 92:1164-1172.
31. Tiwari R, Brown A, Narramaneni S, Sun G, Parang K: Synthesis and evaluation of conformationally constrained peptide analogues as the Src SH3 domain binding ligands. Biochimie 2010, 92:1153-1163.
32. Kumar A, Wang Y, Lin X, Sun G, Parang K: Synthesis and evaluation of 3- phenylpyrazolo[3, 4-d]pyrimidine-peptide conjugates as Src kinase inhibitors. Chem Med Chem 2007, 2:13460-1360.
33. Kumar A, Ye G, Wang Y, Lin X, Sun G, Parang K: Synthesis and structureactivity relationships of linear and conformationally constrained peptide analogues of CIYKYY as Src tyrosine kinase inhibitors. J Med Chem 2006, 49:3395.3401.
34. Nam NH, Lee S, Ye G, Sun G, Parang K: ATP-phosphopeptide conjugates as inhibitors of Src tyrosine kinases. Bioorg Med Chem 2004, 12:5753.5766.
35. Nam NH, Ye G, Sun G, Parang K: Conformationally constrained peptide analogues of pTyr-Glu-Glu-Ile as inhibitors of the Src SH2 domain binding. J Med Chem 2004, 47:3131-3141. (Pubitemid 38702707)
36. Balalaie S, Ramezanpour S, Bararjanian M, Gross JH: DABCO-catalyzed efficient synthesis of naphthopyran derivatives via One-Pot threecomponent condensation reaction at room temperature. Synthetic Commun 2008, 38:1078-1089. (Pubitemid 351364149)
37. Abdolmohammadi S, Balalaie S: Novel and efficient catalysts for the onepot synthesis of 3, 4-dihydropyrano[c]chromene derivatives in aqueous media. Tetrahedron Lett 2007, 48:3299-3303. (Pubitemid 46533987)
38. Chhikara BS, St Jean N, Mandal D, Kumar A, Parang K: Fatty acyl amide derivatives of doxorubicin: synthesis and in vitro anticancer activities. Eur J Med Chem 2011, 46:2037-2042.